Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

Described are methods for producing cannabinoid prodrugs as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents for treating diseases.

Described are methods for producing cannabinoid prodrugs as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents for treating diseases.

The invention relates generally to new compounds of formula (I), wherein R.sub.1, R′.sub.1, R.sub.2, R′.sub.2, R.sub.3, R′.sub.3, R.sub.4 R′.sub.4, R.sub.5, R′.sub.5, R.sub.6, R.sub.7 are independently of one another and denote hydrogen, hydroxyl, C.sub.1 to C.sub.6-alkyl group or R.sub.6 and R.sub.7 form together a C5-C6 ring system, and wherein n=0, 1, 2, 3, or 4. Moreover, the invention relates to the use of one or more compounds of formula (I) in cosmetic or pharmaceutical compositions, which are preferably dermatological compositions and are preferably used topically. ##STR00001##

The invention relates generally to new compounds of formula (I), wherein R.sub.1, R′.sub.1, R.sub.2, R′.sub.2, R.sub.3, R′.sub.3, R.sub.4 R′.sub.4, R.sub.5, R′.sub.5, R.sub.6, R.sub.7 are independently of one another and denote hydrogen, hydroxyl, C.sub.1 to C.sub.6-alkyl group or R.sub.6 and R.sub.7 form together a C5-C6 ring system, and wherein n=0, 1, 2, 3, or 4. Moreover, the invention relates to the use of one or more compounds of formula (I) in cosmetic or pharmaceutical compositions, which are preferably dermatological compositions and are preferably used topically. ##STR00001##

A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound.

A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound.

The present disclosure provides a compound of Formula (I); ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.

Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.